| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2010806 | Pharmacological Reports | 2015 | 11 Pages |
Abstract
In this review, we discuss the association between antidiabetic drugs used in monotherapy or polytherapy and cancer risk, and consider potential mechanisms responsible for the observed effects.
Keywords
EGR-1PPAR γFDAGLP-1 AgonistsT2DMIGF-1RSIRmTORDNASGLT2 InhibitorsTZDsAdenosine TriphosphateATPdeoxyribonucleic acidinsulinSubcutaneous injectionthiazolidinedionesCancer riskRelative riskAntidiabetic drugsDefined daily dosesDiabetes mellitusType 2 diabetes mellitusFood and Drug Administrationbody mass indexBMIconfidence intervalDPP-4 inhibitorsDipeptidyl peptidase-4 inhibitorsstandardized incidence ratiohazard ratioodds ratiomammalian target of rapamycininternational unitPeroxisome proliferator-activated receptor gammainsulin receptorinsulin-like growth factor 1 receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Anna Tokajuk, Edyta Krzyżanowska-Grycel, Adrian Tokajuk, SÅawomir Grycel, Anna Sadowska, Halina Car,